Buscar
Mostrando ítems 1-10 de 34
The Development of Coronavirus 3C-Like Protease (3CLpro) Inhibitors from 2010 to 2020
3CLpro is a key enzyme for the maturation of all coronaviruses and has hence
been recognized as a potent drug target for the treatment of coronavirus infection. The
present review focuses on the status of various efficacious ...
The repurposed drugs suramin and quinacrine cooperatively inhibit sars-cov-2 3clpro in vitro
(2021-01-01)
Since the first report of a new pneumonia disease in December 2019 (Wuhan, China) the WHO reported more than 148 million confirmed cases and 3.1 million losses globally up to now. The causative agent of COVID-19 (SARS-CoV-2) ...
A Computer-Aided Approach for the Discovery of D-Peptides as Inhibitors of SARS-CoV-2 Main Protease
(2022-01-24)
The SARS-CoV-2 main protease, also known as 3-chymotrypsin-like protease (3CLpro), is a cysteine protease responsible for the cleavage of viral polyproteins pp1a and pp1ab, at least, at eleven conserved sites, which leads ...
Novel inhibitors of the main protease enzyme of SARS-CoV-2 identified via molecular dynamics simulation-guided in vitro assay
(2021-06-01)
For the COVID-19 pandemic caused by SARS-CoV-2, there are currently no effective drugs or vaccines to treat this coronavirus infection. In this study, we focus on the main protease enzyme of SARS-CoV-2, 3CLpro, which is ...
Estudo de docking molecular com o fármaco Cloroquina frente à proteína-chave 3CLPRO do SARS-CoV-2
(Editora Inovar, 2020)
Em Wuhan, China, um paciente foi diagnosticado com sintomas atípicos de pneumonia viral. A amostra encontrou um novo coronavírus, chamado de novo coronavírus 2019 (nCoV2019). Em meio a isso, os cientistas estão procurando ...
Análise da afinidade molecular do medicamento Atazanavir frente à proteína-chave 3CLPRO do SARS-CoV-2
(Editora Inovar, 2020)
Em Wuhan, China, ocorreu um surto de pneumonia decorrente de infecções por SARSCoV-2, que até o dia 28 de junho de 2020 já infectou cerca de 10.012.244 pessoas, levando 499.342 a óbito. Diante disso, ainda não existe ...
Estudo in sílico do potencial biológico do antiviral Zanamivir frente á poteína-chave 3CLPRO do SARS-CoV-2
(Editora Inovar, 2020)
O COVID-19 é uma doença respiratória aguda grave causada pela SARS-CoV-2, que
já infectou mais de 10 milhões de pessoas em todo o mundo. Os primeiros casos registrados
foram identificados na cidade de Wuhan, China, em ...